2210P Reprogramming of Pyrimidine Metabolism Drives Tumorigenesis in NF2-deficient Malignant Pleural Mesothelioma

D. Xu,R.A. Schmid,R-W. Peng,Y. Shu
DOI: https://doi.org/10.1016/j.annonc.2023.09.992
IF: 51.769
2023-01-01
Annals of Oncology
Abstract:Malignant pleural mesothelioma (MPM) is a highly aggressive cancer, notoriously known because of limited treatment options and a dismal prognosis. MPM features a difficult-to-target genome dominated by widespread loss of function mutations in tumor suppressor genes (TSGs), among which neurofibromin 2 (NF2) is one of the most altered TSGs and accounts for around 40-50% of MPM patients. Despite extensive and continuous efforts, the underlying pathobiology of NF2-related tumorigenesis remains obscure. In particular, targeted therapies, a mainstay in the clinical management of many other tumors, have not emerged in MPM. In this study, we have taken a genome-wide CRISPR/Cas9 knockout screening to identify therapeutically relevant genetic vulnerabilities in NF2-deficient MPM cells. Further, integrated analysis of multiple-omics data (transcriptome, proteome, and metabolome) based on the gene-edited cell models and patients’ tumor samples was implemented to systematically decipher the molecular basis underlying NF2-facilitated tumorigenesis. Subsequently, in vitro and in vivo preclinical orthotopic mouse models were performed to delineate the genetic dependency of NF2-deficient MPM cells. Here, we show that NF2-deficient MPM cells display a preferential sensitivity towards the disruption of genes involved in de novo pyrimidine metabolism, including CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, dihydroorotase) and DHODH (dihydroorotate dehydrogenase). Further exploration uncovers that the adaptive reprogramming of the de novo pyrimidine synthesis pathway is a critical molecular alteration in the NF2-deficient MPM. In addition, we observe that the constitutive activation of YAP1(Yes-associated protein 1) in NF2-deficient MPM triggers the boosted transcription of rate-limiting enzymes in the de novo pyrimidine synthesis. Coherently, pharmacological inhibition of DHODH exerted a more potent anti-tumor effect in an orthotopic mouse model of MPM. Taken together, our work delineates the molecular basis and metabolic vulnerability driven by NF2 inactivation while also providing a novel therapeutic target to battle against this daunting disease.
What problem does this paper attempt to address?